ABX203 therapeutic Hepatitis B vaccine treatment arm
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Hepatitis B
Conditions
Chronic Hepatitis B
Trial Timeline
Dec 1, 2014 → Dec 1, 2016
NCT ID
NCT02249988About ABX203 therapeutic Hepatitis B vaccine treatment arm
ABX203 therapeutic Hepatitis B vaccine treatment arm is a phase 2/3 stage product being developed by Abivax for Chronic Hepatitis B. The current trial status is completed. This product is registered under clinical trial identifier NCT02249988. Target conditions include Chronic Hepatitis B.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02249988 | Phase 2/3 | Completed |
Competing Products
20 competing products in Chronic Hepatitis B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |